Triple-Negative Breast Cancer (TNBC) Active Not Recruiting Phase 1 / 2 Trials for Selumetinib (DB11689)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02583542A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersTreatment